SCHAUMBURG, Ill., Aug. 4 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, today announced that it has launched ondansetron in 5% dextrose injection in premix bags, an antiemetic and selective 5-HT3 receptor antagonist used to prevent nausea and vomiting caused by chemotherapy. Sagent’s ondansetron in 5% dextrose injection in premix bags is the generic equivalent of GlaxoSmithKline’s ZOFRAN(R) Injection Premixed. Sagent will begin marketing and shipping ondansetron in 5% dextrose injection premix bags immediately.
